Novo Nordisk A/S’s sales showed the weakest growth in four years as the Danish drugmaker loses ground to Eli Lilly & Co. in ...

The US president has flagged higher-than-expected tariffs of up to 250 per cent on drug imports, which is a potential blow to ...

Sales of Novo Nordisk’s diabetes drugs including Ozempic slowed to grow at 8 per cent year on year in the first half, down sharply from its rate last year, as the company loses market share to rival ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Thursday before the bell. Here’s what ...

Eris Lifesciences is using its growing insulin business to position itself as a serious contender in India’s fast-expanding ...

A contract company for a fiber optics provider has hit a water line, forcing Lilly Grove Water Supply to issue a boil-water ...

Trump is pushing drug companies to lower their prices, but experts cast doubt on how effective this endeavor will prove.

(Reuters) -The U.S. Food and Drug Administration on Tuesday approved Ajovy, an injection made by Israeli drugmaker Teva ...

Eli Lilly's stock is lagging the S&P 500 since April, potentially allowing a catch-up trade if results impress. Medicare may ...